Manifiesto sobre los espectáculos cómico taurinos

Las siguientes entidades cívicas, Asociación de Personas con Acondroplasia y otras Displasias Esqueléticas con Enanismo (ADEE España), Asociación Nacional para Problemas de Crecimiento CRECER, AFAPAC, Fundación ALPE Acondroplasia, AFASCOL, AVADOS ALPE, FUNDACION MAGAR, AGAEFA, CANTABRIA ALPE, AFAPA CANARIAS, ABA-ALPE, SARE Acondroplasia, como principales organizaciones de España de defensa de los derechos de las personas con ADEE (Acondroplasia y otras Displasias Esqueléticas con Enanismo), MANIFIESTAN:

—Su total apoyo al posicionamiento del Ministerio de Asuntos Sociales y Agenda 2030 del Gobierno de España de prohibir los espectáculos cómicos taurinos en que se hace mofa de personas con enanismo.

—Las organizaciones firmantes llevan más de 20 años luchando, reivindicando y exigiendo la prohibición de estos espectáculos que denigran la dignidad colectiva y los derechos fundamentales de las personas con ADEE, y que España cumpla con sus obligaciones jurídicas y políticas como Estado parte de la Convención Internacional de los Derechos de las Personas con Discapacidad.

—La vigente regulación del torero cómico incumple la Convención Internacional de los Derechos de las Personas con Discapacidad, (arts. 4 y 15), así como la normativa europea, Acta de los Derechos Fundamentales de la Unión Europea, el Tratado de la Unión Europea o la Directiva 2000/78/CE del Consejo de 27 de noviembre relativa al establecimiento de un marco general para la igualdad de trato en el empleo y la ocupación.

—El Comité sobre los Derechos de las Personas con Discapacidad de las Naciones Unidas, en su informe de 2019, advirtió a España de su preocupación “por los persistentes estereotipos negativos y la representación degradante de las personas con discapacidad, como por ejemplo las personas con enanismo en espectáculos cómico-taurinos (…)”, instándole a que implementara las medidas legislativas pertinentes para derogar la normativa que ampara estos espectáculos contrarios a los derechos humanos de las personas con discapacidad.

—El Congreso de los Diputados en febrero de 2019, aprobó por unanimidad de todos los grupos parlamentaros la Declaración institucional sobre la normativa de la Unión Europea en relación con la situación de las personas que sufren acondroplasia, en la que se comprometían a “Realizar los cambios normativos pertinentes para impedir la celebración de espectáculos públicos y privados que denigran y humillan a las personas con enanismo y, de esta manera, haga cumplir con el mandato de las instituciones internacionales, por la cual España debe tomar medidas pertinentes para modificar todas aquellas medidas legislativas que constituyan discriminación contra las personas con discapacidad”.

—Exigimos, tanto al Gobierno de España como a todas las administraciones públicas con competencias en espectáculos públicos y taurinos, que cumplan con el mandato del Comité sobre los Derechos de las Personas con Discapacidad de las Naciones Unidas y sean coherentes con la Declaración institucional sobre la normativa de la Unión Europea en relación con la situación de las personas que sufren acondroplasia que todos los partidos con representación parlamentaria aprobaron por unanimidad.

Ante el argumento esgrimido de que la prohibición de estos espectáculos conllevaría la pérdida de empleo de estas personas, señalamos:

—Que actualmente existe un Convenio con la Fundación ONCE e INSERTA EMPLEO, y todas las personas que se dedican a estos espectáculos tienen a su disposición un programa específico de inserción y reciclaje profesional y un compromiso de contratación para un empleo digno y decente.

—Que el Gobierno de España se ha comprometido a poner en marcha un plan de inserción y formación laboral para que todas aquellas personas con enanismo que trabajan en espectáculos y actividades denigrantes puedan acceder a un empleo digno y decente.

—Que, en el supuesto de que el Gobierno de España no apruebe el paquete de medidas normativas que prohíban los espectáculos denigrantes y humillantes para las personas con ADEE, las organizaciones firmantes denunciarán a España ante las instituciones europeas y la Convención Internacional de los Derechos de las Personas con Discapacidad.

Resultados Fase 3 Vosoritide

Nota de prensa: BioMarin anuncia resultados finales positivos de los datos de la Fase 3, controlada por placebo, en niños con acondroplasia tratados con Vosoritide

Copiamos la nota de prensa de BioMarin (el link en el título). Es posible usar el traductor de google, dado que la compañía aún no ha publicado la versión en español.

BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide


Placebo-adjusted Increase in Growth Velocity of 1.6 cm/yr (p<0.0001) in Children Treated with Vosoritide Over One Year

Pre-submission Meetings with Health Authorities Planned for H1 2020 to Discuss Marketing Applications

SAN RAFAEL, Calif., Dec. 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today reported positive final results from its randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of vosoritide. The placebo-adjusted change from baseline in growth velocity after one year of treatment with vosoritide, the primary endpoint, was 1.6 cm/yr (p<0.0001). Vosoritide is an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP). The study enrolled 121 children aged 5 to 14 with achondroplasia, the most common form of disproportionate short stature. The results were consistent across the broad patient population studied. Vosoritide was generally well tolerated with no clinically significant blood pressure decreases. Based on these results, the Company plans to meet with health authorities in the first half of 2020 to discuss plans for submitting marketing applications.

"This is an important milestone that further reinforces our confidence in the tremendous potential of vosoritide. The placebo-controlled study demonstrated a strong increase in growth velocity across the broad population studied," said Hank Fuchs, M.D., President Worldwide Research and Development at BioMarin. "These results when combined with the long-term benefits seen in the Phase 2 study provide hope for a significant and sustained benefit for children with achondroplasia. We appreciate the children and their families who have participated in this development program, and we look forward to discussing plans for submitting marketing applications with health authorities. We also plan to present the detailed data from this study at an upcoming medical meeting."

"As a treating physician, it is exciting to see these compelling results of an investigational therapy confirming its potential to be the first medical therapy to treat the underlying cause of achondroplasia," said John A. Phillips, III, M.D., Vanderbilt University Medical Center (David T Karzon Professor of Pediatrics). "Importantly, this data adds to an increasing body of scientific data on a potential breakthrough in the treatment for achondroplasia."

"Growing Stronger supports medical research that has the potential to improve the quality of medical care and make a significant impact on the lives of little people," said Amer Haider, Founder and President of Growing Stronger. "We are hopeful that supporting research and continuing advances in science will accelerate the development of therapeutic choices for families, where there are no medicines available today."

Growing Stronger's mission is to improve the quality of medical care for people through supporting research. The organization raises nonprofit donations that are granted to researchers focused on dwarfism.

Description of Phase 3 Study

The global Phase 3 study is a randomized, double-blind, placebo-controlled study of vosoritide in 121 children with achondroplasia aged 5 to 14 for 52 weeks. (The enrollment age criteria is 5 to 18 per the study protocol.) Vosoritide is being tested in children whose growth plates are still open. This is approximately 25% of people with achondroplasia. Children in this study have completed a minimum six-month baseline study to determine their respective baseline growth velocity prior to entering the Phase 3 study. The primary endpoint of the study is the change in growth velocity from baseline over one year in children treated with vosoritide compared to placebo. A wide range of secondary and exploratory endpoints include anthropometric measures such as height Z-score, body and limb proportionality and joint geometry; biochemical, biomarker and radiological assessments of bone growth and health; and evaluations of health-related quality of life (HRQoL), developmental status, and functional independence. These additional endpoints address the overall impact vosoritide has on achondroplasia and will continue to be evaluated in an ongoing open-label extension study where all subjects receive active treatment.

Vosoritide Safety

Vosoritide, administered at 15ug/kg/day in this Phase 3 randomized, double-blinded placebo-controlled study over one year, was generally well tolerated. The majority of adverse events (AEs) were mild and no serious adverse events were reported as study drug-related. Injection site reactions were the most common drug-related AEs, and all were transient. No clinically significant blood pressure decreases or new safety findings were observed.

About Achondroplasia

Achondroplasia, the most common form of disproportionate short stature in humans, is characterized by slowing of endochondral ossification, which results in disproportionate short stature and disordered architecture in the long bones, spine, face and base of the skull. This condition is caused by a mutation in the fibroblast growth factor receptor 3 gene (FGFR3), a negative regulator of bone growth. Beyond disproportionate short stature, people with achondroplasia can experience serious health complications, including foramen magnum compression, sleep apnea, bowed legs, mid-face hypoplasia, permanent sway of the lower back, spinal stenosis and recurrent ear infections. Some of these complications can result in the need for invasive surgeries such as spinal cord decompression and straightening of bowed legs. In addition, studies show increased mortality at every age.


More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous gene mutation. The worldwide incidence rate of achondroplasia is about one in 25,000 live births. Vosoritide is being tested in children whose growth plates are still "open," typically those under 18 years of age. This is approximately 25% of people with achondroplasia. In the U.S., Europe, Latin America and the Middle East, there are currently no licensed medicines for achondroplasia.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com. Information on such website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the development of BioMarin's vosoritide development program generally and specifically about the results of the Phase 3 trial, the continued clinical development of vosoritide and the timing and conduct of such clinical program; the possible results of such studies, and discussions with health authorities about marketing applications. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: final analysis of the Phase 3 data, results and timing of current and planned preclinical studies and clinical trials of vosoritide; our ability to enroll participants into such clinical trials, our ability to successfully manufacture vosoritide; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning vosoritide; and those other risks and uncertainties detailed from time to time under the caption "Risk Factors" and elsewhere in the BioMarin's Securities and Exchange Commission (SEC) filings, including, without limitation, BioMarin's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and future SEC filings and reports by BioMarin. BioMarin undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.